STOCK TITAN

Fortress Biotech (FBIO) SEC Filings, Nov 2025-Mar 2026

FBIO NASDAQ

Fortress Biotech, Inc. filings document a biopharmaceutical issuer with common stock and 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock listed on the Nasdaq Capital Market. Its SEC record includes Form 8-K reports on operating results, FDA approvals, priority review voucher monetization, credit agreement amendments and subsidiary capital actions.

Proxy materials describe annual meeting matters, board governance, executive compensation and equity awards. Registration statements and material-event filings add disclosure on securities offerings, capital structure, risk factors, material agreements and ownership interests in portfolio companies such as Cyprium Therapeutics and Journey Medical.

Rhea-AI Summary

WEISS MICHAEL S reported acquisition or exercise transactions in this Form 4 filing.

Fortress Biotech, Inc. insider Michael S. Weiss, the Executive Vice Chairman, received a grant of 475,424 shares of common stock on March 18, 2026. These restricted shares were awarded under the company’s Long-Term Incentive Plan and increased his direct holdings to 2,276,562 shares. This is a compensation-related equity award rather than an open-market purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
insider
-
Form 8-K
Rhea-AI Summary

Fortress Biotech’s majority-owned subsidiary Cyprium Therapeutics agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for $205 million in cash, payable at closing. The voucher was granted after ZYCUBO was approved to treat Menkes disease in pediatric patients.

Fortress owns 80.4% of Cyprium’s common stock and expects to receive at least $100 million over time from Cyprium through dividends and intercompany arrangements, subject to closing, taxes, required payments to a National Institutes of Health institute, Cyprium’s preferred stock redemption and other obligations. Fortress also amended its Oaktree credit agreement to ease several financial covenants after the PRV sale and to apply $10 million of proceeds, plus interest and a yield protection premium, to mandatory loan prepayment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
current report
-
Rhea-AI Summary

Fortress Biotech, Inc. reported that the U.S. Food and Drug Administration approved ZYCUBO (copper histidinate, formerly CUTX-101) for the treatment of Menkes disease in pediatric patients. This represents regulatory clearance for a therapy aimed at a rare pediatric condition.

In connection with this FDA approval, a Rare Pediatric Disease Priority Review Voucher was issued and will be transferred to Cyprium Therapeutics, Inc., a majority-owned subsidiary of Fortress Biotech. The company furnished a press release with further details as an exhibit.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
current report
Rhea-AI Summary

Fortress Biotech, Inc. is registering up to 600,000 shares of its common stock for resale by Oaktree Fund Administration, LLC and affiliated selling stockholders. These shares are issuable upon exercise of warrants granted under a credit agreement amendment.

The selling stockholders may sell the shares over time on Nasdaq or in private transactions, using various methods described in the plan of distribution. Fortress will pay the registration costs but will not receive any proceeds from the resale of these shares. Its common stock trades on the Nasdaq Capital Market under the symbol FBIO, and 31,037,937 shares were outstanding as of December 11, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
prospectus
-
EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
other
-
Rhea-AI Summary

Fortress Biotech, Inc. is registering up to 600,000 shares of common stock for potential resale by Oaktree-affiliated selling stockholders. These shares are issuable upon exercise of warrants granted under a December 12, 2025 amendment to Fortress’s senior credit agreement, with an exercise price of $2.62 per share and an expiration date of July 25, 2031. The warrants became immediately exercisable and include anti-dilution adjustments and an option for net exercise without cash payment.

Fortress’s common stock trades on the Nasdaq Capital Market under the symbol FBIO, and the last reported sale price on December 11, 2025 was $2.94 per share. There were 31,037,937 shares outstanding as of that date, which would rise to 31,637,937 shares if all 600,000 warrant shares were issued. Fortress will not receive any proceeds from the resale of these shares but will cover registration expenses, while investors are referred to the company’s incorporated risk factor disclosures for a detailed discussion of risks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.72%
Tags
registration
Rhea-AI Summary

Fortress Biotech, Inc. entered into a first amendment to its term loan credit agreement with Oaktree Fund Administration that extends the loan maturity, adjusts covenants and grants new stock warrants to the lenders. The company initially borrowed $35.0 million under the facility in July 2024 and currently has about $29.5 million outstanding.

The amendment moves the loan’s maturity from July 25, 2027 to June 30, 2028, with quarterly interest payments until maturity. Principal will be repaid based on the outstanding balance as of September 30, 2027: 12.5% due on September 30, 2027, another 12.5% on December 31, 2027, 37.5% on March 31, 2028, and the remaining 37.5% at maturity.

Journey Medical Corporation, a controlled subsidiary, is now subject to higher minimum product net sales covenants, rising from $60.0 million at December 31, 2025 to $80.0 million at December 31, 2026 and each quarter-end thereafter, with an event of default possible if these levels are not met while loan principal exceeds $10.0 million. In connection with the amendment, Fortress granted warrants to purchase up to 600,000 common shares at $2.62 per share, with anti-dilution and price-reset features, immediately exercisable through July 25, 2031 and issued as unregistered securities under Section 4(a)(2), with a planned resale registration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.72%
Tags
current report
-
Form 8-K
Rhea-AI Summary

Fortress Biotech, Inc. reported that the U.S. Food and Drug Administration accepted the resubmission of the New Drug Application (NDA) for CUTX-101 as a Class 1 resubmission and provided a Prescription Drug User Fee Act (PDUFA) target action date of January 14, 2026 for the NDA.

This disclosure highlights a defined regulatory timetable for CUTX-101, giving a clear date for when the FDA expects to take action on the resubmitted application, which is important context for anyone following the company’s drug development efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.31%
Tags
current report
-
Rhea-AI Summary

Fortress Biotech reports that its partner Sentynl Therapeutics has resubmitted the New Drug Application (NDA) for CUTX-101 to the U.S. Food and Drug Administration. CUTX-101 (copper histidinate) is intended to treat Menkes disease in pediatric patients and previously received a Complete Response Letter from the FDA on October 1, 2025. Sentynl, which assumed full responsibility for development and commercialization of CUTX-101 from Cyprium Therapeutics in December 2023, is leading the resubmission. Cyprium will retain ownership of any Priority Review Voucher that may be issued if the NDA is approved and is eligible to receive royalties and up to $129 million in aggregate development and sales milestone payments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
current report
Rhea-AI Summary

Fortress Biotech (FBIO) filed its Q3 2025 10‑Q, showing higher sales and a swing to quarterly profitability aided by non-operating gains. Net revenue was $17.6 million versus $14.6 million a year ago, while loss from operations was $6.8 million. Other income of $15.7 million drove net income of $8.8 million; income attributable to Fortress was $5.9 million and net income to common stockholders was $3.7 million (diluted EPS $0.11).

Year to date, net revenue reached $47.2 million and the company recorded a $27.1 million gain from deconsolidating Checkpoint after its sale to Sun Pharma, plus $2.6 million other income tied to Urica’s Crystalys transaction. Cash and cash equivalents were $86.2 million, up from $57.3 million at year‑end, as financing and investing inflows offset operating cash use of $53.2 million.

Total liabilities fell to $116.2 million and total stockholders’ equity improved to $65.2 million. Common shares outstanding were 31,037,937 as of November 10, 2025. The filing states Parent Entity cash of $38.6 million is sufficient for at least 12 months following the filing date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
quarterly report

FAQ

How many Fortress Biotech (FBIO) SEC filings are available on StockTitan?

StockTitan tracks 34 SEC filings for Fortress Biotech (FBIO), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Fortress Biotech (FBIO)?

The most recent SEC filing for Fortress Biotech (FBIO) was filed on November 13, 2026.